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Ivermectin is increasingly being used to treat scabies, especially crusted (Norwegian) scabies. However, treat-
ment failures, recrudescence, and reinfection can occur, even after multiple doses. Ivermectin resistance has
been documented for some intestinal helminths in animals with intensive ivermectin exposure. Ivermectin
resistance has also been induced in arthropods in laboratory experiments but, to date, has not been documented
among arthropods in nature. We report clinical and in vitro evidence of ivermectin resistance in 2 patients
with multiple recurrences of crusted scabies who had previously received 30 and 58 doses of ivermectin over
4 and 4.5 years, respectively. As predicted, ivermectin resistance in scabies mites can develop after intensive
ivermectin use.
Ivermectin is increasingly being used to treat scabies,
especially in those with hyperinfestation (crusted or
Norwegian scabies) [1, 2]. Scabies is endemic in many
remote Aboriginal communities in the Northern Ter-
ritory of Australia, and a minority of patients develop
crusted scabies. Unlike in most reports of crusted sca-
bies, the cases we treat in these communities often in-
volve no overt immunosuppression, and the reason that
this select cohort develops hyperinfestation remains un-
clear [3]. We have been using ivermectin since 1992 to
treat 150 patients with crusted scabies. However, treat-
ment failure or early recrudescence is common after
single-dose ivermectin, and multiple doses have usually
been required to achieve a cure [3]. With adequate
treatment, there is excellent clinical response, with
crusts fully resolved and normal skin or residual patchy
depigmentation. Nevertheless, exposure of these sus-
ceptible individuals to scabies in their communities
continues, and recurrent crusted scabies several months
to a year after initial cure is common [4]. By means of
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genotyping of Sarcoptes scabiei mites from patients with
repeated infestations, we found that, although the ma-
jority of recurrent scabies are probably the result of
reinfestation from inadequately treated contacts, there
was evidence that, in cases of severe crusted scabies,
even treatment with 3 doses of ivermectin administered
14 days apart may be inadequate to prevent relapse [5].
We therefore increased the ivermectin regimen for pa-
tients with severe crusted scabies to 5 doses (each 200
mg/kg) administered on treatment days 1, 2, 15, 16, and
29, on the basis of a protocol for strongyloidiasis com-
plicating AIDS [6].
By use of a simple in vitro assay to assess the survival
of scabies mites on petri dishes coated with various
acaricides, we previously found no evidence of de-
creased ivermectin sensitivity in mites obtained from
patients who were administered multiple courses of
ivermectin [7], including 1 patient who had had re-
ceived 150 doses. However, we now report 2 patients
with recurrent severe crusted scabies who developed in
vivo and in vitro resistance to ivermectin after receiving
multiple ivermectin doses.
MATERIALS AND METHODS
Larvae, nymphal instars, and adult S. scabiei were sep-
arated from skin scrapings obtained from patients with
crusted scabies before and during treatment. Ovicidal
activity was not measured. To circumvent differences
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Figure 1. Kaplan-Meier survival curves of scabies mites obtained from
patient 1 in 1999 (n p 10), 2000 (n p 14), and 2001 (n p 9) after
admissions to the hospital for treatment of crusted scabies. Mites were
tested in petri dishes coated with ivermectin at a concentration of 100
mg/g. * .Pp .0048
in survival ability, all mites were tested within 3 h of being
obtained, as described elsewhere [7]. The determination of sen-
sitivity to ivermectin of mite populations was assessed at a
concentration of 100 mg/g of ivermectin (Equimec Paste; Merial
Australia) diluted in Emulsifying Ointment British Pharma-
copoeia 88 (BP88) (Sigma Pharmaceuticals). In earlier studies
in our laboratory, we had established 100 mg/g as the ivermectin
concentration for in vitro testing, which was adapted from the
in vitro acaricidal experiments of Brimer et al. [8]. At a con-
centration of 100 mg/g ivermectin, we demonstrated a mean S.
scabiei mite killing time of 60 min [7]. Approximately 0.1 g of
the test product was applied in a thin layer with cotton swabs
to the bottom, top, and sides of 36-mm petri dishes. BP88-
coated petri dishes were used as controls. Determination of
mite survival after placement on the petri dishes was as de-
scribed elsewhere [7].
Results were analyzed by use of a log-rank test for survival
(SPSS software, version 10.0.5; SPSS). The study was approved
by the Human Research Ethics Committee of the Northern
Territory Department of Health and Community Services and
Menzies School of Health Research.
RESULTS
Case report 1. A 36-year-old Aboriginal woman from a re-
mote coastal community in the tropical Top End of the
Northern Territory of Australia sought care in January 2000
for severe crusted scabies involving hands and feet, thighs,
trunk, and buttocks. She had a history of recurrent crusted
scabies since 1992. The results of multiple immunological in-
vestigations, including serological testing for HIV and human
T cell leukemia virus 1 (HTLV-1), were negative, and T cell
subsets were normal. Since 1995, the patient had received 30
doses of ivermectin, 17 of which were administered during
1999, including 2 doses that were administered in December
1999. A further course of therapy with ivermectin together with
topical 5% permethrin cream and topical keratolytic therapy
with 10% urea and 5% lactic acid in sorbolene cream was
initiated. Live S. scabiei mites from skin scrapings were seen
microscopically up to day 26 after commencement of iver-
mectin therapy, by which time in vitro testing had shown de-
creased sensitivity of mites, with some mites alive 9 h after in
vitro exposure to ivermectin at a concentration of 100 mg/g
(figure 1). Because no in vitro resistance to the other acaricides
tested was observed, topical 5% permethrin cream was in-
creased to treatment on alternate days, and the condition of
the patient’s skin steadily improved, with the first clear skin
scrapings occurring on day 30 after initiation of therapy. Two
months later, the patient had no evidence of scabies, but there
was considerable depigmentation of her hands and feet. In April
2001, she again presented with crusted scabies, but in vitro
testing showed no ivermectin resistance (figure 1), and she
responded to 7 doses of ivermectin administered at a higher
dose (21 mg per dose, at a concentration of 280 mg/kg) over
a 28-day period with topical 25% benzyl benzoate and kera-
tolytic therapy.
Case report 2. A 47-year-old Aboriginal man from a dif-
ferent remote Top End community presented in August 2000
with severe crusted scabies involving all limbs, buttocks, and
lower back. Since 1996, he had received 58 doses of ivermectin
for multiple episodes of recurrent crusted scabies. The results
of multiple immunological investigations, including serological
testing for HIV and HTLV-1, were negative, and T cell subsets
were normal. The patient received seven 18-mg doses of iver-
mectin at a concentration of 270 mg/kg during the next 30 days,
together with topical 5% permethrin cream alternating with
topical keratolytic therapy with 10% urea and 5% lactic acid
in sorbolene cream, and subsequently 12% salicylic acid in
cetomacrogel cream. He also required intravenous antibiotics
to treat secondary sepsis. Although there was gradual clinical
improvement during a month of treatment, multiple live mites
were still present on days 12, 19, and 26 after commencement
of ivermectin therapy, and the patient had to leave the hospital
for family reasons after receiving his seventh dose of ivermectin.
The patient subsequently returned to the hospital 3 weeks after
receiving his last dose of ivermectin, and the condition of his
crusted scabies was clinically worse than at the time of dis-
charge. There were numerous live mites still present. In vitro
testing of mites obtained at admission showed some with pro-
longed survival, after exposure to ivermectin at a concentration
of 100 mg/g (figure 2).
Because of the failure of our standard topical therapy regimen
and the apparent in vitro and in vivo ivermectin resistance, we
commenced therapy with topical 25% benzyl benzoate with tea
tree oil added (to make a 5% tea tree oil solution). The rationale
for this was that benzyl benzoate and 5% tea tree oil were
e10 • CID 2004:39 (1 July) • Currie et al.
Figure 2. Kaplan-Meier survival curves of scabies mites obtained from
patient 2 in 1997 (n p 7), 2000 (n p 63), and 2001 (n p 13) after
admissions to the hospital for treatment of crusted scabies. Mites were
tested in petri dishes coated with ivermectin at a concentration of 100
mg/g. * .P ! .00001
consistently the topical scabicides that killed scabies mites the
quickest in our earlier in vitro studies [7]. The severe burning
sensation that the patient felt for several minutes after appli-
cation of the benzyl benzoate was controlled by inhalation of
50% nitrous oxide/50% oxygen mixture. He was administered
11 doses of the combination topical therapy over a 4-week
period, as well as a further 7-dose course of ivermectin therapy
(18 mg/dose), and the condition of his skin rapidly improved.
Skin scrapings obtained 10 days after this therapy was initiated
showed only 2 of 100 mites to be alive, and at 20 days, no
mites were present. At discharge, the patient had no clinical or
microscopic evidence of scabies, although there was consid-
erable depigmentation of his feet and lower legs. In May 2001,
he again presented with crusted scabies, but in vitro testing
showed no evidence of ivermectin resistance (figure 2). His
illness responded to 6 doses of ivermectin administered over a
21-day period together with topical 25% benzyl benzoate/5%
tea tree oil and topical keratolytics.
Figure 3 shows in vitro survival curves for ivermectin ex-
posure for the mites obtained from patients 1 and 2 after their
admissions in 2000 (at which time in vivo ivermectin resistance
was present), compared with that for mites obtained from pa-
tients 1 and 2 at other admissions and that for mites from 3
other patients with crusted scabies.
DISCUSSION
To our knowledge, this is the first report of in vivo or in vitro
ivermectin resistance in S. scabiei. Ivermectin insensitivity or
differential responsiveness has emerged as a major problem in
a number of intestinal nematodes of goats, sheep, and cattle,
with most cases being related to intensive ivermectin use over
a period of several years [9, 10]. No ivermectin-resistant ar-
thropod has previously been reported from any animal or hu-
man infestations or field situation [9, 10], although there are
reports showing ivermectin resistance can be induced in the
laboratory under intense drug exposure in the horn fly (Hae-
matobia irritans) [11], fruit fly (Drosophila melanogaster) [12],
and a species of tick (Boophilus microplus) [13].
The potential for development of ivermectin-resistant S. sca-
biei was a concern in treating our patients, who have required
many doses of ivermectin for treatment of their recurrent
crusted scabies [5, 7]. Unlike most patients previously docu-
mented with crusted scabies, our patients have not had a severe
immunosuppressive illness and, therefore, have survived long
enough to require an unprecedented number of ivermectin
doses. The reason for the development of crusted scabies in
our patients remains uncertain, although the possibility of a
specific immune defect predisposing them to hyperinfestation
with S. scabiei is currently being investigated. Genotyping stud-
ies [5] and the development of ordinary scabies in hospital staff
who were infected from these patients with crusted scabies
make differences in S. scabiei virulence an unlikely explanation.
The exact mechanisms of ivermectin action and resistance
remain to be elucidated and appear to vary between organisms.
Ivermectin inhibits signal transmission at the neuromuscular
junction of some arthropods by stimulating release of the in-
hibitory neurotransmitter gamma-aminobutyric acid from pre-
synaptic nerve terminals [2]. However, paralysis and death of
invertebrate nerve and muscle cells has also been attributed to
ivermectin binding to glutamate-gated chloride channels, re-
sulting in increased chloride ion permeability and hyperpolar-
ization [14]. Ivermectin is also believed to bind to and be
transported by a P-glycoprotein membrane transport protein
[15]. These efflux pump proteins are thought to be involved
in the multidrug-resistance phenotype seen in some human
cancers, and mutations in the Plasmodium falciparum gene en-
coding the P-glycoprotein homologue have recently been
shown to confer antimalarial drug resistance [16]. Alterations
in P-glycoprotein gene structure and/or its transcription have
been described in ivermectin-resistant sheep nematode para-
sites, Haemonchus contortus [15]. Another potential mechanism
for ivermectin resistance is mutation in the glutamate-gated
chloride channels that modulate ivermectin activity. There is
also support for this mechanism from other studies with H.
contortus [17] and from chemical mutagenesis studies in fruit
flies [12]. It is therefore possible that, under intense drug se-
lection pressure, mutations of scabies P-glycoprotein encoding
genes and/or of the gene family encoding the glutamate-gated
chloride channels may account for our cases of ivermectin
resistance.
The presence of ivermectin-sensitive mites in the recurrences
that our 2 patients experienced in 2001 suggests that the earlier
ivermectin-resistant scabies infections were eradicated, but that
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Figure 3. Kaplan-Meier survival curves of ivermectin-resistant scabies
mites obtained from patients 1 and 2 in 2000 (n p 77), in comparison
with nonivermectin-resistant mites obtained from patients 1 and 2 and
from 3 other patients with crusted scabies (n p 50). * .P ! .00001
our patients were reinfected from contacts after they returned
to their communities. These 2 patients have had 74 and 91
doses of ivermectin, respectively. Attempts at prophylaxis
against recurrent infection by giving monthly ivermectin doses
have failed to prevent the infection in several individuals we
have treated (unpublished results). We are currently assessing
the administration of topical therapy with permethrin or benzyl
benzoate once every 2 weeks as prophylaxis for high-risk in-
dividuals who have had recurrent crusted scabies. However, we
are concerned about the possible emergence of resistance to
these topical therapies with such a program. Although resis-
tance of head lice (Pediculus capitis) to 1% permethrin has been
widely reported [2, 18], there has to date been no documented
clinical evidence of tolerance of scabies mites to 5% permethrin
[19], although we reported evidence for increasing in vitro
killing time [7]. Our in vitro testing also showed that 25%
benzyl benzoate killed scabies mites more quickly than did 5%
permethrin [7], but clinical resistance to benzyl benzoate has
been suspected elsewhere [20]. Lindane (1% gamma benzene
hexachloride) has been successfully used for many years in
treating scabies [21], but in vivo and in vitro mite resistance
to lindane has occasionally been documented [2, 22–24], and
lindane has been withdrawn from sale in several countries,
including Australia, because of well-documented but rare in-
stances of neurotoxicity and aplastic anemia [25].
The rapid in vitro scabicidal action of 5% tea tree oil [7, 26]
and its successful use in combination with benzyl benzoate in
1 of our patients warrants further study of this (and possibly
other) combination topical therapies. We found that the com-
bination of 5% tea tree oil in 25% benzyl benzoate killed scabies
mites in vitro at least as quickly as benzyl benzoate alone (un-
published observation).
Initial recommendations for the use of ivermectin to treat
crusted scabies were for a single dose at a concentration of 200
mg/kg, with a second dose administered 2 weeks later for re-
fractory cases [1]. The importance of concomitant keratolytic
therapy and topical scabicides to kill mites in the thick crusts
has been emphasized [1, 2, 27, 28]. The difficulty in eradicating
scabies mites in patients with particularly severe crusted scabies
was supported by the presence of live mites in 1 patient 19
days after ivermectin therapy was initiated, despite a good (but
incomplete) clinical response; in vitro testing showing no ev-
idence of ivermectin resistance [28]. A recent comparative study
concluded that, in treating cases of ordinary scabies, a single
application of 5% permethrin cream was superior to a single
200 mg/kg dose of ivermectin [29]. It was suggested that iver-
mectin may not be ovicidal because of inadequate penetration
of the thick eggshell, as well as possibly being ineffective against
the younger stages of the parasite inside the egg because, at
that point in the life cycle, the parasite’s nervous system has
not yet developed. This supports the rationale for a second
dose of ivermectin to kill mites emerging from eggs after ad-
ministration of the first dose. However, the timing of the second
dose may be important: a study of experimental scabies chal-
lenge in pigs showed efficacy of ivermectin persisting for only
9 days after administration of a single dose [30]. Therefore, a
weekly dosing interval may be superior to dosing every 2 weeks
in treating cases of crusted scabies. The possibility of the use
of doses exceeding 200 mg/kg has also been raised [27, 31].
In light of concerns that a 2-week dosing interval is inade-
quate, we have further modified our protocol for treating re-
current crusted scabies to a 5-dose regimen with doses of 200
mg/kg administered on days 1, 2, 8, 9, and 15 of therapy, with
an additional 2 doses on days 22 and 29 for the most severe
cases. Further dosing and dose-interval studies are required in
order to define optimal ivermectin regimens for treating crusted
scabies of varying degrees of severity.
The emergence of ivermectin resistance in S. scabiei after
intensive ivermectin use over a period of several years reflects
the failure to control the current community epidemics of sca-
bies in our region, with treated individuals often being rein-
fected from untreated contacts. There is now an even more
urgent reason to focus on community-based prevention and
control programs [4, 23].
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